X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation

Yuvraj_pawp by Yuvraj_pawp
31st July 2014
in Market Moves

Unique Pizza and Subs Corporation (“Unique,” OTC Markets Groups Inc.: OTC Pink: UPZS), a Delaware Corporation, is pleased to announce it has signed a distribution agreement with Larasan Pharmaceutical Corporation (“Larasan”), a nature-based pharmaceutical company that produces and distributes health-enhancing products.  According to the agreement, US-based Larasan will work with Unique to help distribute its health-oriented, gourmet 6″ frozen pizza through Larasan’s vast distribution network throughout China which includes several hundreds of thousands of retail points. Unique’s gourmet pizza utilizes natural cheeses, probiotics and enzymes that are deemed to be healthier than standard frozen pizzas, and appeals to the growing worldwide trend in health-conscious fast food.

The term of the agreement, signed by James C. Vowler President & CEO of Unique and by Sumair Mitroo, CEO of Larasan, covers the period April 22, 2014 through July 22, 2015, with the option of continuation.

Dr. M. S. Reddy, Senior Advisor of Unique Pizza and Subs Corporation, said, “We have been speaking with Sumair since the beginning of the year about his company’s immense distribution network and its ability to distribute our industry leading gourmet quality Uniquepizzas. This agreement is a big step towards getting our product to market and we look forward to working with Sumair and his team.  I have been working with the pizza industry for more than 40 years and I have contributed to the success and growth of many of the industry leaders. I have now found what I believe the pizza community has always needed a company that understands what quality really means. Jim has a passion and understanding of the pizza business like no one I have ever met and his drive for success without compromise in quality while maintaining integrity and loyalty is the reason I am on board.”

Larasan’s CEO, Sumair Mitroo, said, “Although Larasan is a pharmaceutical company with its own line of products that combine nature and bio-science to increase health, we will distribute other products that connect with this vision.  People around the world love pizza, and the demand is there for a gourmet and healthy pizza that can be served quickly.  After meeting the team at Unique Pizza, I was quickly convinced about their capabilities to fill this demand.  Jim is very driven and focused on improving his pizza business, and Dr. Reddy is already well known for his contributions in the pizza industry with his specialized cheese formulations.  Moreover, Dr. Reddy’s deep knowledge and expertise in probiotics will make significant impact on the success of this venture.  Our team is excited to work with Unique Pizza and distribute a truly unique pizza in China and Asia.”

About Larasan Pharmaceutical Corporation

Larasan is a nature-based pharmaceutical company with a broad range of transdermal (skin patch), oral, and liquid OTC products, for the prevention and/or treatment of pain, performance, bug bites, and energy.  Its products combine nature and bio-science through improved delivery systems to increase health.  Based in the US with operations in China, Larasan is an early stage pharmaceutical company with distribution in the US and Asia. For more information, visit www.larasan.com.

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward- looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions. There are no financials in this press release so this is not needed and undermines the release.

SOURCE Unique Pizza and Subs Corporation

Previous Post

Eisai and Arena Pharmaceuticals Announce BELVIQ(R) (lorcaserin HCl) CIV Nominated a Second Time for the Prix Galien Award in the Best Pharmaceutical Agent Category

Next Post

Meda agrees to acquire Rottapharm for €2.3bn

Related Posts

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m
Market Moves

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

18th July 2022
Could The Long Deckline In Biotechnology M&A Be Ending
Featured

Could The Long Deckline In Biotechnology M&A Be Ending

16th July 2022
EMA Advises Recall of AbbVie, Biogen MS Drug
Market Moves

No Rush In Indian Generic Drug Firms To Launch COVID Products

16th July 2022
Market Moves

Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter

8th April 2022
Regeneron, Intellia to develop CRISPR/Cas9-based treatments
Market Moves

Metagenomi Closes Oversubscribed $175M Series B Financing to Advance Therapeutic Pipeline and Expand Novel Gene Editing Platform

29th January 2022
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe
Market Moves

Indian Pharma Industry To Grow By 9-11% In FY22- ICRA

7th January 2022
Next Post

Meda agrees to acquire Rottapharm for €2.3bn

Latest News

FDA Approvals

NHS Acquires Potentially Lifesaving Breast Cancer Medication

9th November 2022
Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

9th November 2022
Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In